1316 related articles for article (PubMed ID: 9755289)
21. Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.
Baraldi PG; Fruttarolo F; Tabrizi MA; Preti D; Romagnoli R; El-Kashef H; Moorman A; Varani K; Gessi S; Merighi S; Borea PA
J Med Chem; 2003 Mar; 46(7):1229-41. PubMed ID: 12646033
[TBL] [Abstract][Full Text] [Related]
22. A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives.
van Muijlwijk-Koezen JE; Timmerman H; Link R; van der Goot H; IJzerman AP
J Med Chem; 1998 Oct; 41(21):3987-93. PubMed ID: 9767636
[TBL] [Abstract][Full Text] [Related]
23. A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds.
van Muijlwijk-Koezen JE; Timmerman H; Link R; van der Goot H; Ijzerman AP
J Med Chem; 1998 Oct; 41(21):3994-4000. PubMed ID: 9767637
[TBL] [Abstract][Full Text] [Related]
24. Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.
Pastorin G; Da Ros T; Spalluto G; Deflorian F; Moro S; Cacciari B; Baraldi PG; Gessi S; Varani K; Borea PA
J Med Chem; 2003 Sep; 46(20):4287-96. PubMed ID: 13678407
[TBL] [Abstract][Full Text] [Related]
25. Novel insights into how purines regulate pituitary cell function.
Rees DA; Scanlon MF; Ham J
Clin Sci (Lond); 2003 May; 104(5):467-81. PubMed ID: 12578557
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of adenosine receptors in human neutrophils: up-regulation by specific Th1 cytokines and lipopolysaccharide.
Fortin A; Harbour D; Fernandes M; Borgeat P; Bourgoin S
J Leukoc Biol; 2006 Mar; 79(3):574-85. PubMed ID: 16387843
[TBL] [Abstract][Full Text] [Related]
27. Purines '96.
Alexander SP; Ford AP
Trends Pharmacol Sci; 1996 Nov; 17(11):385-8. PubMed ID: 8990951
[No Abstract] [Full Text] [Related]
28. Role of Purinergic Signaling in Acupuncture Therapeutics.
Lv ZY; Yang YQ; Yin LM
Am J Chin Med; 2021; 49(3):645-659. PubMed ID: 33641652
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology of adenosine A2A receptors and therapeutic applications.
Fredholm BB; Cunha RA; Svenningsson P
Curr Top Med Chem; 2003; 3(4):413-26. PubMed ID: 12570759
[TBL] [Abstract][Full Text] [Related]
30. Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor.
van Tilburg EW; van der Klein PA; de Groote M; Beukers MW; IJzerman AP
Bioorg Med Chem Lett; 2001 Aug; 11(15):2017-9. PubMed ID: 11454470
[TBL] [Abstract][Full Text] [Related]
31. Coffee, caffeine, chlorogenic acid, and the purinergic system.
Stefanello N; Spanevello RM; Passamonti S; Porciúncula L; Bonan CD; Olabiyi AA; Teixeira da Rocha JB; Assmann CE; Morsch VM; Schetinger MRC
Food Chem Toxicol; 2019 Jan; 123():298-313. PubMed ID: 30291944
[TBL] [Abstract][Full Text] [Related]
32. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins.
Klinger M; Freissmuth M; Nanoff C
Cell Signal; 2002 Feb; 14(2):99-108. PubMed ID: 11781133
[TBL] [Abstract][Full Text] [Related]
33. Adenosine and ATP: from receptor structure to clinical applications.
Kennedy C; IJzerman A
Trends Pharmacol Sci; 1994 Sep; 15(9):311-2. PubMed ID: 7992379
[No Abstract] [Full Text] [Related]
34. Adenosine and ATP: progress in their receptors' structures and functions.
Khakh BS; Kennedy C
Trends Pharmacol Sci; 1998 Feb; 19(2):39-41. PubMed ID: 9550938
[No Abstract] [Full Text] [Related]
35. Purinergic signaling in neural development.
Zimmermann H
Semin Cell Dev Biol; 2011 Apr; 22(2):194-204. PubMed ID: 21320621
[TBL] [Abstract][Full Text] [Related]
36. Targeting the purinergic pathway in breast cancer and its therapeutic applications.
de Araújo JB; Kerkhoff VV; de Oliveira Maciel SFV; de Resende E Silva DT
Purinergic Signal; 2021 Jun; 17(2):179-200. PubMed ID: 33576905
[TBL] [Abstract][Full Text] [Related]
37. Purinergic signaling, DAMPs, and inflammation.
Di Virgilio F; Sarti AC; Coutinho-Silva R
Am J Physiol Cell Physiol; 2020 May; 318(5):C832-C835. PubMed ID: 32159362
[TBL] [Abstract][Full Text] [Related]
38. Adenosine receptors: new opportunities for future drugs.
Poulsen SA; Quinn RJ
Bioorg Med Chem; 1998 Jun; 6(6):619-41. PubMed ID: 9681130
[TBL] [Abstract][Full Text] [Related]
39. Adenosine and ATP receptors.
Sawynok J
Handb Exp Pharmacol; 2007; (177):309-28. PubMed ID: 17087128
[TBL] [Abstract][Full Text] [Related]
40. The birth and postnatal development of purinergic signalling.
Burnstock G; Fredholm BB; North RA; Verkhratsky A
Acta Physiol (Oxf); 2010 Jun; 199(2):93-147. PubMed ID: 20345419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
